Overview

A New Application of Amiloride in the Treatment of Patient With Chronic Kidney Disease In Reducing Urinary PROtein

Status:
Completed
Trial end date:
2020-08-01
Target enrollment:
0
Participant gender:
All
Summary
Nowadays, the prevalence of chronic kidney disease (CKD) in China is about 10.8%,and nearly 120 million people suffer from CKD, which has become a serious public health problem in China. Study confirmed that proteinuria is an independent risk factor for the continuous deterioration of glomerular filtration rate (GFR) in patients with CKD. So it is of great significance to explore the strategy of reducing proteinuria. According to our previous study, Amiloride can inhibit the expression of uPAR in podocytes and reduce proteinuria, This clinical trial aims to evaluate the effect and safety of Amiloride in decreasing proteinuria for patients with Chronic Kidney Disease.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Guangdong General Hospital
Guangdong Provincial People's Hospital
Treatments:
Amiloride
Hydrochlorothiazide
Criteria
Inclusion Criteria:

- Patients at the age of more than 14 years old with chronic kidney disease

- Good compliance of treatment

- PCR≥500mg/g.cr ，more than double confirmed

- Patients who written informed consent

Exclusion Criteria:

- less than 14 years of age

- eGFR≤30ml/min.1.73m2；

- poor compliance of treatment

- Previously intolerant or allergic to hydrochlorothiazide

- Patients with history of gout within six months

- Patients with active infection

- Patients with severe cardiopulmonary disease and dysfunction of central nervous system

- history of malignancy

- life expectancy is less than 1 years

- women who are pregnant,lactating and lack of contraception.

- enrolled in other clinical trials within 3 months

- patients who have used immunosuppressive agents or corticosteroids recently or in the
past 12 weeks.

- patients without informed consent written or who enable or unwilling to comply with
protocol approved by researchers.